Cecchini M, et al. - The safety and effectiveness of oxaliplatin combined with TAS-102 (an alternative and non-cross-resistant anti-metabolite) for refractory metastatic colorectal cancer (mCRC) was determined in phase 1 of TAS-OX, a 3+3 dose-escalating study with a starting dose of TAS-102 25 mg/m² and oxaliplatin 85 mg/m² with three dose levels. Researchers identified 12 patients that were able to be evaluated for dose-limiting toxicity (DLT). As per outcomes, the recommended phase 2 dose (RP2D) of TAS-102 is 35 mg/m²in combination with oxaliplatin 85 mg/m². They observed no DLTs and no unexpected AEs. This heavily pretreated patient population displayed encouraging disease control rate. Researchers are enrolling for phase 2 at this dose.